Maravai Lifesciences Holdings (MRVI) Net Cash Flow (2020 - 2026)

Maravai Lifesciences Holdings' Net Cash Flow history runs 7 years deep, the most recent figure standing at -$51.0 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 36.29% year-over-year to -$51.0 million in Q1 2026; TTM through Mar 2026 was -$119.1 million, a 56.97% increase from a year earlier, with the FY2025 full-year figure at -$105.5 million, up 58.24% from the prior year.
• Net Cash Flow fell to -$51.0 million in Q1 2026 per MRVI's latest filing, from -$26.7 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $119.2 million in Q2 2022 and bottomed at -$255.8 million in Q4 2024.
• The 5-year median for Net Cash Flow is -$13.3 million (2024), against an average of -$22.7 million.
• Biggest YoY gain for Net Cash Flow was 973.2% in 2024; the steepest drop was 5408.46% in 2024.
• Year by year, Net Cash Flow stood at $14.7 million in 2022, then slumped by 131.6% to -$4.6 million in 2023, then slumped by 5408.46% to -$255.8 million in 2024, then soared by 89.56% to -$26.7 million in 2025, then sank by 91.02% to -$51.0 million in 2026.
• Per Business Quant, the three latest MRVI Net Cash Flow figures stand at -$51.0 million (Q1 2026), -$26.7 million (Q4 2025), and -$26.3 million (Q3 2025).